| |||||||||||||||||||||||||||||||||||
# of Animals | Phenotype | Strain | Sex | Value | Units | Conditions | Record ID | ||||||||||||||||||||||||||||
24 | maximum body weight loss to initial body weight ratio | DA.PVG.1AV1-(D4Rat155-Spr) | both | 10.6 | % | pristane (150 ul) | 69806 | pristane (150 ul) | |||||||||||||||||||||||||||
24 | percentage of study population developing experimental arthritis during a period of time | DA.PVG.1AV1-(D4Rat155-Spr) | both | 100 | % | pristane (150 ul) | 69719 | pristane (150 ul) | |||||||||||||||||||||||||||
24 | post-insult time to onset of experimental arthritis | DA.PVG.1AV1-(D4Rat155-Spr) | both | 12.5 | d | pristane (150 ul) | 69787 | pristane (150 ul) | |||||||||||||||||||||||||||
24 | serum orosomucoid 1 level | DA.PVG.1AV1-(D4Rat155-Spr) | both | 1060 | mg/l | pristane (150 ul) | 69766 | pristane (150 ul) |